InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | 2026-05-21 | Zeiher Bernhardt G | Director | Purchase | 5,000 | $5.86 | $29K | 5,000 | View ↗ | |
| 2026-05-04 | 2026-05-04 | Sethuraman Natarajan | President, Research & Develop. | Sale | 25.9K | $15.39 | $399K | 216.3K | View ↗ | |
| 2026-05-04 | 2026-05-04 | Dowden Nathan J | President & COO | Sale | 15.0K | $15.33 | $230K | 198.6K | View ↗ | |
| 2026-04-01 | 2026-04-02 | WENTWORTH KORY JAMES | Chief Financial Officer | Sale | 2,500 | $12.95 | $32K | 119.0K | View ↗ | |
| 2026-03-10 | 2026-03-11 | Dowden Nathan J | President & COO | Sale | 11.9K | $13.05 | $155K | 198.6K | View ↗ |
| Metric | FY2021 | FY2020 |
|---|---|---|
| Research and development | $35.9M+70.2% | $21.1M |
| General and administrative | $15.2M+173.2% | $5.6M |
| Total operating expenses | $51.1M+91.7% | $26.7M |
| Loss from operations | -$51.1M-91.7% | -$26.7M |
| Interest and other (expense) income, net | -$31K-121.5% | $144K |
| Total other (expense) income, net | -$31K-121.5% | $144K |
| Net loss | -$51.2M-92.9% | -$26.5M |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -$8K+66.0% | -$24K |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -$8K+66.0% | -$24K |
| Weighted-average common shares outstanding, basic (in shares) | $6.27B+467.1% | $1.11B |
| Weighted-average common shares outstanding, diluted (in shares) | $6.27B+467.1% | $1.11B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Entrada Therapeutics, Inc. (TRDA) Q1 2026 Earnings Call Transcript
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
Entrada’s stock drops as DMD drug’s efficacy falls short
Sarepta Dives; Can 2026 Be The Reset Year For Its Controversial Gene Therapy?